Delays in cancer screening during the COVID-19 pandemic will likely cause a significant increase in cancer cases that could have been caught earlier with screening, and may now be diagnosed at later stages, placing an increased burden on an already strained healthcare system, according to a new research article published in the Journal of the American College of Surgeons.
FDA—under the leadership of cyber-iconoclast and new director of the agency’s Center for Biologics Evaluation and Research, Vinay Prasad—is taking a new approach to COVID-19 vaccines.
